Researchers at University College London have identified a specific mechanism by which GLP-1 receptor agonists, the drug class behind semaglutide and similar weight-loss medications, can relax tiny blood vessels in the heart and restore blood flow after a heart attack. The finding, published in Nature Communications in March 2026, offers the clearest explanation yet for why these drugs might protect cardiac tissue during the critical minutes after an artery is reopened. With up to half of heart attack patients experiencing a dangerous complication called no-reflow, where blood fails to reach damaged muscle despite a cleared artery, the discovery raises a pressing question: can drugs already prescribed to millions be repurposed for emergency cardiac care?
Why no-reflow after heart attacks demands new solutions
When a patient suffers a ST-segment elevation myocardial infarction, or STEMI, the standard treatment is primary percutaneous coronary intervention, a procedure that physically reopens the blocked artery. But restoring flow in the large vessel does not guarantee that blood reaches the smallest capillaries feeding the heart muscle. This failure, known as microvascular obstruction or no-reflow, affects a large share of STEMI patients and is strongly linked to worse outcomes. A pooled analysis of seven trials found that microvascular obstruction after STEMI and PCI is associated with adverse clinical events including death and heart-failure hospitalization.
No approved drug specifically targets no-reflow during acute heart attack care. That gap is what makes the new UCL research significant. Co-lead authors Svetlana Mastitskaya and David Attwell showed that activating the GLP-1 receptor with a compound called exendin-4 relaxes coronary capillary pericytes, the contractile cells wrapped around the smallest blood vessels, through ATP-sensitive potassium (KATP) channels. In animal models of ischemia and reperfusion, this pericyte relaxation improved perfusion and reduced no-reflow. The mechanism is distinct from the metabolic and anti-inflammatory effects that GLP-1 receptor agonists are already known for, suggesting a direct vascular action at the capillary level.
For patients, the practical implication is straightforward. If a drug given alongside standard PCI can keep those tiny vessels open, more heart muscle survives, and the risk of later heart failure drops. The UCL team framed the clinical stakes bluntly: up to roughly half of patients experience no-reflow, according to the university’s summary of the research, and those who do face elevated risk of death or heart-failure admission within a year.
Earlier trials with GLP-1 agonists in STEMI patients
The UCL pericyte study is mechanistic, not clinical. It explains how GLP-1 receptor activation might work at the vessel wall, but it did not measure outcomes in human heart attack patients. Several earlier randomized trials, however, did test GLP-1 receptor agonists during acute STEMI care and produced encouraging signals.
A randomized trial in STEMI patients undergoing primary PCI evaluated intravenous exenatide started just before reperfusion and continued for several hours. Using cardiac MRI, investigators measured infarct size and myocardial salvage index about three months later. The study found that exenatide reduced reperfusion injury, with a higher proportion of myocardium saved in the treated group, especially among patients who reached the hospital quickly.
A related investigation added important nuance: exenatide’s benefit on final infarct size appeared most clearly in patients with a shorter total ischemic time. In those whose arteries were reopened promptly, the drug’s effect on salvaging at-risk myocardium was more pronounced, reinforcing the idea that any GLP-1–based protocol would need to be deployed rapidly, ideally in the ambulance or immediately on arrival in the cath lab.
Another randomized controlled trial tested liraglutide, a longer-acting GLP-1 receptor agonist, in STEMI patients treated with PCI. In that study, participants received daily liraglutide for several days after their heart attack, and left ventricular ejection fraction was assessed at three months. The trial, indexed in a cardiology database, suggested that liraglutide could modestly improve systolic function compared with standard care alone, hinting that the cardioprotective effect might extend across the GLP-1 class rather than being unique to exenatide.
The COMBAT-MI trial later explored a two-by-two factorial design, combining exenatide with remote ischemic conditioning-brief cycles of arm ischemia using a blood pressure cuff-during primary PCI. Imaging endpoints included infarct size, myocardial salvage, left ventricular function, and microvascular obstruction volume. While the factorial design made it harder to isolate each intervention’s contribution, the study helped map how pharmacologic and non-pharmacologic strategies might be layered to protect the microcirculation.
Collectively, these trials show that GLP-1 receptor agonists can influence infarct-related injury when given during acute care. However, they were relatively small and focused on imaging and functional endpoints. None was powered to detect differences in all-cause mortality or heart-failure hospitalization over longer follow-up. That limitation leaves clinicians without definitive proof that acute GLP-1 therapy during STEMI should become routine practice.
What chronic prevention trials can – and cannot – tell us
Evidence from chronic cardiovascular prevention adds another piece to the puzzle. The SELECT trial enrolled people with established cardiovascular disease and overweight or obesity but without diabetes, treating them with once-weekly semaglutide 2.4 mg or placebo for years. Investigators reported that semaglutide reduced major cardiovascular events such as cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke compared with placebo.
Those findings confirm that GLP-1 receptor agonists can lower cardiovascular risk in high-risk populations, likely through a mix of weight loss, blood pressure reduction, improved lipids, and anti-inflammatory effects. But SELECT does not answer the acute-care question raised by the UCL pericyte work. The trial did not test semaglutide at the moment of reperfusion, nor did it examine microvascular obstruction or no-reflow as endpoints. Chronic prevention and emergency cardioprotection remain distinct arenas, even if they share a common drug class.
From bench to bedside: what would a STEMI protocol look like?
Translating the UCL mechanism into practice would require carefully designed clinical trials. One likely approach would test a short-acting GLP-1 receptor agonist administered intravenously or subcutaneously just before or during primary PCI, with dosing tailored to achieve rapid receptor activation in the coronary microcirculation. Key imaging endpoints would include microvascular obstruction volume, myocardial salvage index, and infarct size on cardiac MRI, alongside clinical outcomes such as heart-failure hospitalization and all-cause mortality at 6 to 12 months.
Safety would be central. GLP-1 receptor agonists can cause nausea, vomiting, and transient drops in blood pressure-side effects that could complicate care in hemodynamically unstable patients. Dose-finding studies in lower-risk cohorts might be needed first to define regimens that maximize microvascular benefit while minimizing hemodynamic stress. Interactions with other drugs commonly used during PCI, such as anticoagulants and antiplatelet agents, would also require close scrutiny.
Another unresolved question is whether the microvascular benefits seen with exendin-4 in experimental models extend equally to newer agents like semaglutide or tirzepatide. Different GLP-1 receptor agonists vary in potency, half-life, and tissue distribution. The UCL data support a receptor-mediated mechanism in coronary pericytes, but comparative studies would be needed to determine which agents-and which routes of administration-best target the heart’s capillary network in the acute setting.
A promising but unproven strategy
For now, GLP-1 receptor agonists remain unapproved for treating no-reflow or microvascular obstruction during heart attacks. The UCL findings provide a compelling mechanistic rationale, and earlier STEMI trials with exenatide and liraglutide offer supportive but incomplete clinical evidence. Meanwhile, large prevention studies like SELECT underscore the broader cardiovascular relevance of this drug class without resolving how, or whether, it should be used in the cath lab.
If future randomized trials confirm that rapid GLP-1 receptor activation can reliably keep capillaries open after PCI-translating into fewer heart-failure admissions and lower mortality-the standard of care for STEMI could shift. A therapy originally developed for diabetes and weight management might become part of the emergency toolkit for salvaging endangered heart muscle. Until then, the promise of GLP-1–based microvascular protection remains a hypothesis: biologically plausible, clinically intriguing, and waiting for definitive answers.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
